利奈唑胺在多重耐药细菌药物治疗中的应用综述

N. S. Mendes, M. Costa, T. Paulino, F. Agostinho, M. Ribeiro, R. Paludo, W. Rodrigues, C. B. Miguel
{"title":"利奈唑胺在多重耐药细菌药物治疗中的应用综述","authors":"N. S. Mendes, M. Costa, T. Paulino, F. Agostinho, M. Ribeiro, R. Paludo, W. Rodrigues, C. B. Miguel","doi":"10.4172/2155-9597.1000320","DOIUrl":null,"url":null,"abstract":"After the description of an element with ability to combat the infectious processes originating from bacteria, starts a race for survival between the interrelationship of species, bacterial and human. With the evolution scientifictechnical, the man was able to synthesize new antibacterial substances, on the other hand the mechanisms of gene evolution enabled the emergence of multidrug-resistant bacteria. Some of this organisms are frequent on hospital environment and have high adaptability to new drugs, such as Staphylococcus aureus and Enterococcus spp. resistant to oxacillin and vancomycin, considered drugs of choice against multidrug-resistant microorganisms. So, a new antibiotics class was developed, superior to vancomycin and oxazolidinone, the linezolid. Thus, the present study aimed at understanding the use of linezolid in drug therapy against multi-resistant bacteria. To perform this study, a literature review of last 10 years was performed. In 2002, after the liberation of the use of linezolid as treatment for infectious processes against gram-positive bacteria, this drug was commonly used throughout the world. Similarly, the pressure of natural selection stood out, and there were records of resistant strains to linezolid. As prospects for control of infections caused by these resistant strains, was approved by the FDA in 2014 the use of drugs with linezolid resistant anti-strains activity. However, we conclude that, in addition to natural selection and genetic variation process, human behavior regarding the use of antibiotics, increases the selection of resistant microorganisms to antibiotic, including linezolid.","PeriodicalId":15045,"journal":{"name":"Journal of Bacteriology & Parasitology","volume":"110 1","pages":"1-5"},"PeriodicalIF":0.0000,"publicationDate":"2017-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Linezolid use in Medicine Therapy against Multiresistant Bacteria-AReview\",\"authors\":\"N. S. Mendes, M. Costa, T. Paulino, F. Agostinho, M. Ribeiro, R. Paludo, W. Rodrigues, C. B. Miguel\",\"doi\":\"10.4172/2155-9597.1000320\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"After the description of an element with ability to combat the infectious processes originating from bacteria, starts a race for survival between the interrelationship of species, bacterial and human. With the evolution scientifictechnical, the man was able to synthesize new antibacterial substances, on the other hand the mechanisms of gene evolution enabled the emergence of multidrug-resistant bacteria. Some of this organisms are frequent on hospital environment and have high adaptability to new drugs, such as Staphylococcus aureus and Enterococcus spp. resistant to oxacillin and vancomycin, considered drugs of choice against multidrug-resistant microorganisms. So, a new antibiotics class was developed, superior to vancomycin and oxazolidinone, the linezolid. Thus, the present study aimed at understanding the use of linezolid in drug therapy against multi-resistant bacteria. To perform this study, a literature review of last 10 years was performed. In 2002, after the liberation of the use of linezolid as treatment for infectious processes against gram-positive bacteria, this drug was commonly used throughout the world. Similarly, the pressure of natural selection stood out, and there were records of resistant strains to linezolid. As prospects for control of infections caused by these resistant strains, was approved by the FDA in 2014 the use of drugs with linezolid resistant anti-strains activity. However, we conclude that, in addition to natural selection and genetic variation process, human behavior regarding the use of antibiotics, increases the selection of resistant microorganisms to antibiotic, including linezolid.\",\"PeriodicalId\":15045,\"journal\":{\"name\":\"Journal of Bacteriology & Parasitology\",\"volume\":\"110 1\",\"pages\":\"1-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Bacteriology & Parasitology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2155-9597.1000320\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bacteriology & Parasitology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2155-9597.1000320","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在描述了一种能够对抗细菌感染过程的元素之后,开始了一场物种间的生存竞赛,细菌和人类。随着科学技术的进化,人类能够合成新的抗菌物质,另一方面,基因进化的机制使多重耐药细菌的出现成为可能。其中一些微生物常见于医院环境,对新药具有较高的适应性,如耐氧西林和万古霉素的金黄色葡萄球菌和肠球菌,被认为是对抗多重耐药微生物的首选药物。因此,开发了一种优于万古霉素和恶唑烷酮的新型抗生素——利奈唑胺。因此,本研究旨在了解利奈唑胺在多重耐药细菌药物治疗中的应用。为了进行这项研究,我们进行了近10年的文献回顾。2002年,利奈唑胺作为治疗革兰氏阳性菌感染过程的药物得到解放后,这种药物在世界各地得到普遍使用。同样,自然选择的压力也很突出,有对利奈唑胺产生抗性的菌株的记录。由于具有控制这些耐药菌株引起的感染的前景,FDA于2014年批准使用具有利奈唑胺耐药抗菌株活性的药物。然而,我们得出结论,除了自然选择和遗传变异过程外,人类使用抗生素的行为增加了抗生素耐药微生物的选择,包括利奈唑胺。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Linezolid use in Medicine Therapy against Multiresistant Bacteria-AReview
After the description of an element with ability to combat the infectious processes originating from bacteria, starts a race for survival between the interrelationship of species, bacterial and human. With the evolution scientifictechnical, the man was able to synthesize new antibacterial substances, on the other hand the mechanisms of gene evolution enabled the emergence of multidrug-resistant bacteria. Some of this organisms are frequent on hospital environment and have high adaptability to new drugs, such as Staphylococcus aureus and Enterococcus spp. resistant to oxacillin and vancomycin, considered drugs of choice against multidrug-resistant microorganisms. So, a new antibiotics class was developed, superior to vancomycin and oxazolidinone, the linezolid. Thus, the present study aimed at understanding the use of linezolid in drug therapy against multi-resistant bacteria. To perform this study, a literature review of last 10 years was performed. In 2002, after the liberation of the use of linezolid as treatment for infectious processes against gram-positive bacteria, this drug was commonly used throughout the world. Similarly, the pressure of natural selection stood out, and there were records of resistant strains to linezolid. As prospects for control of infections caused by these resistant strains, was approved by the FDA in 2014 the use of drugs with linezolid resistant anti-strains activity. However, we conclude that, in addition to natural selection and genetic variation process, human behavior regarding the use of antibiotics, increases the selection of resistant microorganisms to antibiotic, including linezolid.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Antigenic Structural Similarity as a Predictor for Antibody Cross-Reactivity What is the Probability that a Vaccinated Person is Shielded from COVID-19? Severe Rhinocerebral Mucormycosis Case Developed after COVID-19 Prevalence and Epidemiology of Gastrointestinal Parasites in Cattle in Different Zones of Tehsil Chakwal, Punjab, Pakistan Characterization, Associated Risk Factors and Possible Treatment of Healthcare Associated Methicillin-Resistant Staphylococcus aureus (HA-MRSA) and Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1